1'-acetylspiro[1H-indole-3,4'-piperidine]-2-one | 742067-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1'-acetylspiro[1H-indole-3,4'-piperidine]-2-one
• CAS: 742067-28-3
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: NGIDPXBDWZYHQI-UHFFFAOYSA-N

物化性质

• 沸点：
  501.2±50.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  螺[吲哚啉-3,4-哌啶]-2-酮 、 乙酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1'-acetylspiro[1H-indole-3,4'-piperidine]-2-one
  参考文献：
  名称：

  [EN] SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
  [FR] PYRROLOPYRIMIDINES SPIRO-SUBSTITUEES

  摘要：

  该发明提供了式（I）的化合物或其药用可接受的盐或酯的公式（I），其中符号的含义如描述中所定义。所述化合物是猫hepsin K和/或猫hepsin S的抑制剂，并且对于治疗猫hepsin K和/或猫hepsin S参与的疾病和医疗状况是有用的，例如各种疾病，包括神经病痛、炎症、类风湿性关节炎、骨关节炎、骨质疏松症、多发性硬化和肿瘤。

  公开号：

  WO2004076455A1

文献信息

• [EN] SPIROHETEROCYCLIC DERIVATIVES AS CRHR2 ANTAGONIST<br/>[FR] DÉRIVÉS SPIROHÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DE CRHR2
  申请人：RAQUALIA PHARMA INC

  公开号：WO2021145401A1

  公开（公告）日：2021-07-22

  The present invention relates to spiroheterocyclic derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR2 is involved.

  本发明涉及对CRHR2具有拮抗活性的螺环杂环衍生物，用于治疗或预防涉及CRHR2的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及CRHR2的疾病中使用这些化合物和组合物。
• SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
  申请人：Irie Osamu

  公开号：US20090186889A1

  公开（公告）日：2009-07-23

  The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof formula I wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.

  该发明提供了I式化合物或其药学上可接受的盐或酯，其中符号的含义如描述中所定义。所述化合物是cathepsin K和/或cathepsin S的抑制剂，可用于治疗与cathepsin K和/或cathepsin S有关的疾病和医疗条件，例如各种紊乱，包括神经病性疼痛、炎症、类风湿性关节炎、骨关节炎、骨质疏松症、多发性硬化症和肿瘤。
• 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF
  申请人：Novartis AG

  公开号：EP1592426B1

  公开（公告）日：2007-12-19
• TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE
  申请人：Iomet Pharma Ltd.

  公开号：EP3082802B1

  公开（公告）日：2020-02-26
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.